Found: 15
Select item for more details and to access through your institution.
N6‐isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity.
- Published in:
- FEBS Open Bio, 2024, v. 14, n. 5, p. 843, doi. 10.1002/2211-5463.13766
- By:
- Publication type:
- Article
Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children.
- Published in:
- Diabetologia, 2024, v. 67, n. 4, p. 714, doi. 10.1007/s00125-023-06075-3
- By:
- Publication type:
- Article
Anti‐viral innate immunity: Is it where type 1 diabetes really begins?
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 5, p. 1, doi. 10.1002/dmrr.3623
- By:
- Publication type:
- Article
Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes.
- Published in:
- Diabetologia, 2023, v. 66, n. 1, p. 132, doi. 10.1007/s00125-022-05812-4
- By:
- Publication type:
- Article
N6-Isopentenyladenosine Impairs Mitochondrial Metabolism through Inhibition of EGFR Translocation on Mitochondria in Glioblastoma Cells.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6044, doi. 10.3390/cancers14246044
- By:
- Publication type:
- Article
High levels of blood circulating immune checkpoint molecules in children with new-onset type 1 diabetes are associated with the risk of developing an additional autoimmune disease.
- Published in:
- Diabetologia, 2022, v. 65, n. 8, p. 1390, doi. 10.1007/s00125-022-05724-3
- By:
- Publication type:
- Article
Plasma circulating miR-23~27~24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes.
- Published in:
- Diabetologia, 2020, v. 63, n. 12, p. 2699, doi. 10.1007/s00125-020-05237-x
- By:
- Publication type:
- Article
CD4<sup>+</sup> T Cell Defects in a Mulibrey Patient With Specific TRIM37 Mutations.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.01742
- By:
- Publication type:
- Article
Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
- Published in:
- 2020
- By:
- Publication type:
- corrected article
miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
- Published in:
- British Journal of Cancer, 2020, v. 122, n. 9, p. 1354, doi. 10.1038/s41416-020-0773-2
- By:
- Publication type:
- Article
miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Molecular Mechanisms Controlling Foxp3 Expression in Health and Autoimmunity: From Epigenetic to Post-translational Regulation.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2019.03136
- By:
- Publication type:
- Article
Blood Co-Circulating Extracellular microRNAs and Immune Cell Subsets Associate with Type 1 Diabetes Severity.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 2, p. 1, doi. 10.3390/ijms21020477
- By:
- Publication type:
- Article
Metabolism and Autoimmune Responses: The microRNA Connection.
- Published in:
- Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.01969
- By:
- Publication type:
- Article
Type 2 Diabetes: How Much of an Autoimmune Disease?
- Published in:
- Frontiers in Endocrinology, 2019, p. 1, doi. 10.3389/fendo.2019.00451
- By:
- Publication type:
- Article